EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Cryoballoon Versus Radiofrequency Ablation for Persistent Atrial Fibrillation: Meta‐Analysis of Randomized Trials

Harroop Bola, Aksaan Arif, Joshua J. Hon, Gayathri Giritharan, Prachur Khandelwal, Rodrick Avakian, Amar Rai, Kiran Haresh Kumar Patel, Fu Siong Ng

Pacing and Clinical Electrophysiology · 2026-11 · 49 (11) · 1692-1705

DOI: 10.1111/pace.70350 ↗
AbstractBibliografische Angaben

Abstract

ABSTRACT Introduction Pulmonary vein isolation (PVI) alone achieves modest arrhythmia freedom in persistent atrial fibrillation (PeAF). Cryoballoon ablation (CBA) offers a single‐shot alternative to radiofrequency ablation (RFA) that streamlines procedural workflow. We aimed to quantify the clinical efficacy, procedural efficiency, and safety of CBA versus RFA through a meta‐analysis of randomized controlled trials (RCTs). Methods and Results Systematic review of PubMed, Embase, and Scopus identified 5 RCTs enrolling 1,091 patients (515 CBA, 576 RFA). The primary endpoint was 12‐month freedom from any atrial arrhythmia, with isolated AF, and atrial tachycardia/flutter evaluated as secondary endpoints. Random‐effects models generated relative risks (RRs) and mean differences (MDs) with 95% confidence intervals (CI). Time‐to‐event data were pooled using a generic inverse‐variance approach to derive hazard ratios (HR). CBA and RFA demonstrated equivalent freedom from any arrhythmia (RR 0.97, 95% CI 0.81–1.15; p = 0.71). Time‐to‐event analysis corroborated a comparable recurrence hazard (HR 0.91, 95% CI 0.67–1.24; p = 0.56; I 2 = 0%). Repeat ablation rates were identical (RR 0.93; p = 0.50). CBA significantly reduced procedural time (MD −45.37 min; p < 0.0001), while major complications were comparable (1.5% vs. 2.7%; p = 0.18). Trial sequential analysis indicated that further randomization is unlikely to demonstrate superiority. Conclusion In PeAF, CBA and RFA achieve equivalent 12‐month arrhythmia‐free survival and comparable repeat‐ablation rates, while CBA confers a highly significant reduction in procedural time. However, reliance on 12‐month follow‐up and heterogeneous rhythm surveillance protocols may limit assessments of true long‐term durability.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →